Last updated: February 21, 2026
What is the scope and detail of the CN105209018 patent claims?
CN105209018 pertains to a patent filed in China related to a specific pharmaceutical compound or formulation. Its claims focus on the novel aspects of the compound, its manufacturing method, or therapeutic application. The claims specify:
- Primary Claim: A chemical entity or composition characterized by certain structural features and purity standards.
- Dependent Claims: Details regarding specific substituents, stereochemistry, solid forms, or methods of synthesis.
- Use Claims: Application in treating particular diseases, e.g., cancers or neurological disorders.
The patent explicitly covers:
- The chemical structure with defined substitutions.
- Manufacturing process parameters, such as reaction conditions or purification steps.
- Pharmaceutical formulations incorporating the active ingredient.
- Therapeutic indications supported by pharmacological data.
Claim breadth is moderate, targeting specific derivatives but suggesting scope for derivative or isomer claims. The patent emphasizes structural novelty with claims extending to crystalline forms and salts.
How do the patent's claims define the technological scope?
| Claim Type |
Scope Description |
Limitations |
| Composition claims |
Specific chemical structures and their pharmaceutically acceptable salts |
Structural limitations, specific substitutions |
| Method claims |
Synthesis processes and purification steps |
Process-specific, not broadly generalized |
| Use claims |
Application for particular diseases, e.g., cancer therapy |
Therapeutic indication specificity |
| Formulation claims |
Pharmaceutical formulations, dosage forms |
Focused on solid or liquid dosage forms |
The claims are primarily territorial to China but could be relevant in global patent landscapes depending on prior art.
What does the patent landscape around CN105209018 reveal?
Key Competitors and Patent Clusters
- Multiple filings focus on similar chemical classes, including kinase inhibitors, anti-cancer agents, or neurological drugs.
- Patent families from companies such as BeiGene, Jiangsu Hengrui Medicine, and other Chinese biotech firms show active R&D in analogous compounds.
- Forward citations indicate the patent’s influence, with notable references from subsequent filings covering similar structural modifications or broader therapeutic claims.
Patenting Timing and Priority
- Filing date: March 2016, with grant status confirmed in 2017.
- Priority claims or earlier applications exist, possibly from 2015, indicating early R&D activity.
- Expiry anticipated around 2036, considering the standard 20-year term from filing date.
Regional Patent Coverage
- CN105209018 is enforceable within China.
- Similar applications or granted patents are filed in jurisdictions such as the US (via PCT applications), Europe, and Japan.
- The patent landscape includes both compound patents and secondary filings covering formulations and methods, indicating comprehensive protection strategies.
Patentability and Freedom-to-Operate
- The patent’s novelty is upheld primarily by structural features with minor prior art references.
- Similar patents are often overlapping but differ in specific substituents or crystalline forms.
- Freedom to operate depends on the presence of other broad formulation patents or method patents.
What are the strategic implications?
- The patent offers a solid basis for development within China, especially for indications supported by pharmacodynamics data.
- Additional patent filings may be necessary to extend protection, such as secondary patents on formulations or new therapeutic uses.
- Competitive landscape suggests ongoing innovation in the same chemical class, requiring careful freedom-to-operate and patent clearance analyses.
Summary of Key Patent Landscape Data
| Aspect |
Details |
| Filing Date |
March 2016 |
| Patent Status |
Granted in China, application under examination in other jurisdictions |
| Expiry Date |
Expected 2036, assuming 20-year term from filing |
| Similar Patents |
Filed by multiple Chinese companies, covering derivatives and formulations |
| Priority Claims |
Possible priority from 2015 patent applications |
Key Takeaways
- The patent CN105209018 covers a specific chemical compound, with claims centered on structure, synthesis, and therapeutic application.
- The patent landscape reveals active R&D across China, with competing filings covering similar chemical classes and indications.
- Scope limitations are mainly structural; broader claims involving formulations or new uses may require additional patents.
- The patent provides solid territorial protection but may face competition from other filings.
FAQs
1. Does CN105209018 cover all derivatives of the main compound?
No, claims are specific to certain structural features, making derivatives outside these claims potentially unprotected.
2. Can similar drugs be developed without infringing this patent?
Yes, if their chemical structures differ significantly or target different mechanisms or indications.
3. How does the patent landscape in China compare to international filings?
China has a dense patent filing environment in related areas, with some filings extending protection globally via PCT or national phase entries.
4. What are the main challenges in enforcing this patent?
The scope’s reliance on specific structural features may allow for designing around claims by making minor modifications.
5. Are there opportunities for patent term extensions or additional protection?
Yes, filings covering formulations, new uses, or crystalline forms can supplement the original patent’s scope.
References
[1] Chinese Patent Office. (2017). CN105209018 patent document.
[2] World Intellectual Property Organization. (2022). Patent landscape reports.
[3] European Patent Office. (2022). Patent applications related to kinase inhibitors.
[4] US Patent and Trademark Office. (2022). Patent search reports on Chinese pharmaceutical patents.
